Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA Filed
Marketed
Ovarian Cancer (2nd line maintenance) */PK Study
Mainland China, HK & Macau (China)
Ovarian Cancer (1st line maintenance)
IO Combo in Gastric, Ovarian, Non Small Cell Lung Cancer (NSCLC)
Glioblastoma (GBM) *- Optune
Hong Kong (China), mainland China
Mesothelioma*
NSCLC
Brain Metastases
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer
Gastrointestinal Stromal Tumors (GIST) (4th Line)
GIST (2nd Line)
Other, i.e. Advanced Systemic Mastocytosis, Glioma
Infectious Disease and Autoimmune
Note: [1] B-NHL, B-cell non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [2] Combo therapy; [3] Combo and mono therapy.